Loading clinical trials...
Loading clinical trials...
Type I interferonopathies are rare autoinflammatory disorders caused by genetic defects and associated with significant morbidity and mortality. These diseases are refractory to conventional immunosuppressive therapies. They typically occur in childhood, although disease onset in adulthood has been observed. The clinical spectrum is wide and mainly involves the central nervous system. Joint involvement is also common, and more rarely, haematological features such as cytopenias or immunodeficiency may be observed. Nearly all patients show consistent over-activation of the type I IFN pathway, as evidenced, the expression of IFN-stimulated genes, the so-called 'interferon signature'. To date, the natural history of interferonopathies remains unclear. In this context, the establishment of a natural history of type I interferonopathy in patients is proposed to elucidate the pathophysiological mechanisms and identify biomarkers for diagnosis, prognosis, and disease activity, with the aim of better characterising the diversity of interferonopathies. The main objective is to characterise the evolution of the pathology in paediatric and adult patients with type I interferonopathies. The overall aim of this research is to propose therapeutic options tailored to patient phenotypes and to better define patient sub-groups in order to optimise the preparation of future clinical trials.
Age
All ages
Sex
ALL
Healthy Volunteers
No
Medical University Innsbruck
Innsbruck, Austria
Antwerp University Hospital
Antwerp, Belgium
Children's Hospital Zagreb
Zagreb, Croatia
Motol University Hospital
Prague, Czechia
CHU d'Angers
Angers, France
Hôpital de Mercy - CHR Metz Thionville
Ars-Laquenexy, France
CHU de Besançon
Besançon, France
CHU de Bordeaux
Bordeaux, France
CHU Morvan
Brest, France
Hôpital Femme Mère Enfant - HCL
Bron, France
Start Date
October 1, 2025
Primary Completion Date
October 1, 2045
Completion Date
October 1, 2045
Last Updated
February 13, 2026
500
ESTIMATED participants
Lead Sponsor
Imagine Institute
NCT06235580
NCT06555965
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions